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CJM 126 is an intriguing compound which emanated from a drug
discovery programme initially aimed at developing tyrosine kinase
inhibitors (Stevens et al, 1994). It was found to inhibit the
growth of human-derived breast cancer cell lines irrespective of
ER status. The unusual biphasic dose–response elicited by CJM
126 against ER+ and ER– breast cancer cell lines has been
described (Bradshaw et al, 1998a; 1998b). Substitution of
2-(4-aminophenyl)benzothiazoles in the 3¢ position with a halogen
atom or a methyl group (Figure 1) furnished these antitumour
agents with remarkable potency and selectivity (Shi et al, 1996). In
vitro, IC50 values fell below 0.01 mM in cultures of sensitive cell
lines of breast (MCF-7, MDA 468, T47D), ovarian (IGROV1),
renal (TK10) and colon (COLO 205, HCT 116) origin. In vivo,
responsive xenograft tumours included ER+ MCF-7 and BO, ER-
MaTu, MT-1 and MT-2 breast (Shi et al, 1996) as well as COLO
205 and HCT 116 colon (J Double and M. Bibby, personal
communication).
Currently, selection of a clinical candidate awaits results of toxi-
cological investigations. However, precise mechanism(s) of action
remain obscure. 2-(4-Aminophenyl)benzothiazoles comprise a
distinct mechanistic class of antitumour agent. Computerized
pattern recognition (COMPARE) algorithm analyses (Weinstein
et al, 1997) have failed to identify a biological target.
Elucidation of biochemical mechanisms of resistance has
contributed immensely to knowledge of mechanisms of anticancer
drug action at the cellular and molecular level, as exemplified by
methotrexate and doxorubicin (Sinha et al, 1987; Akman et al,
1990; Batist et al, 1986). Acquired drug resistance is the most
common reason for failure of drug treatment in cancer patients
with initially-sensitive tumours. Therefore the study of resistance
mechanisms may lead to improvements in therapy following
modification of drug structures such that a specific mechanism is
no longer effective.
Two cell lines with acquired stable resistance to CJM 126 have
been established to probe the mechanisms of action of this series
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Summary 2-(4-aminophenyl)benzothiazole (CJM 126) elicits potent growth inhibition in human-derived breast carcinoma cell lines,
including oestrogen receptor-positive (ER+) MCF-7wt cells. Analogues substituted in the 3¢ position with I (DF 129), CH3 (DF 203), or CI (DF
229) possess an extended profile of antitumour activity with remarkable selective activity in cell lines derived from solid tumours associated
with poor prognosis, e.g. breast, ovarian, renal and colon. Growth inhibition occurs via unknown, possibly novel mechanism(s) of action. Two
cell lines have been derived from sensitive MCF-7wt breast cancer cells (IC50 value < 0.001 mM) following long-term exposure to 10 nM or 10
mM CJM 126, MCF-710 nM 126 and MCF-710 mM 126 respectively, which demonstrate acquired resistance to this agent (IC50 > 30 mM) and cross-
resistance to DF 129, DF 203 and DF 229. Sensitivity to tamoxifen, benzo[a]pyrene (BP), mitomyin C, doxorubicin and actinomycin D is
retained. Resistance may, in part, be conferred by the constitutively increased expression of bcl-2 and p53 proteins detected in MCF-710 nM 126
and MCF-710 mM 126 lysates. Significantly decreased depletion of CJM 126 (30 mM) from nutrient medium of MCF-710 nM 126 cells was observed
with predominantly cytoplasmic drug localization and negligible DNA strand breaks. N-acetyl transferase (NAT)1 and NAT2 proteins were
expressed by all three MCF-7 sub-lines, but significantly higher expression of NAT2 was accompanied by enhanced acetylation efficacy in
MCF-710 nM 126 cells. In contrast, CJM 126 (30 mM) was rapidly depleted from nutrient medium of MCF-710 mM 126 culture and accessed nuclei of
these cells exerting damage to DNA. The major biotransformation product of CJM 126 in MCF-710 mM 126 cells was 2-(4-aminophenyl)-6-
hydroxybenzothiazole (6-OH 126). This metabolite possessed no antitumour activity. Accordingly, in this sub-line, low constitutive expression
and activity of cytochrome P450 (CYP) 1A1 was detected. © 2000 Cancer Research Campaign
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Figure 1 Structure of 2-(4-aminophenyl)benzothiazoles.
R1 R2 R3 NSC no
CJM 126 H H H 34445
DF 129 I H H 674496
DF 203 CH3 H H 674495
DF229 CI H H 682303
DF 128 H COCH3 H 33006
6-OH 126 H H OH 703785Acquired resistance to 2-(4-aminophenyl)benzothiazole 271
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of agents. The variant lines, MCF-710 nM 126 and MCF-710 mM 126
were derived from MCF-7wt cells following prolonged exposure to
10 nM or 10 mM CJM 126 respectively.
Efforts to elucidate biochemical mechanisms conferring
acquired resistance are reported herein. We have compared in the
three cell lines the effects of exposure to 2-(4-
aminophenyl)benzothiazoles on growth and DNA integrity.
Evidence for cross-resistance to tamoxifen, BP, DNA damaging
agents cisplatin, mitomycin C, the DNA intercalating agent
doxorubicin and the antibiotic inhibitor of RNA synthesis actino-
mycin D has been studied, together with expression of genes
purported to play a key role in cell survival. Depletion of CJM 126
from nutrient media, its biotransformation, intracellular distribu-
tion and the roles of xenobiotic metabolizing enzymes (NAT1,
NAT2 and CYP1A1) have also been considered.
MATERIALS AND METHODS
CJM 126, DF 129, DF 203 and DF 229 were synthesized
according to published methods (Shi et al, 1996). Stock solutions
of drugs (10 mM) were prepared in DMSO and stored, protected
from light at 4°C for 4 weeks. RPMI 1640 tissue culture medium
was obtained from Gibco (Paisley, UK). Foetal calf serum (FCS)
was purchased from Globepharm (Esher, Surrey, UK). BDH
(Merck, Poole, Dorset, UK) supplied fluorochrome mounting
medium. NAT1 and NAT2 1° antibodies (abs), raised in rabbits
were donated by Dr Lesley Stanley; specific abs directed against
wt p53 (clones PAb 1801 and D-01), mutant p53 (clone PAb 240)
and bcl-2 (clone 4D7) were purchased from Amersham (Bucks,
UK). Anti-rabbit, anti-mouse 2° abs and reagents for enhanced
chemiluminescence (ECL) detection were supplied by Pierce
(Rockford, Illinois, USA). Abs (1°, 2°) specific for CYP1A1
detection, as well as the positive control sample of CYP1A1
microsomes were obtained from Gentest Corporation (Woburn,
MA, USA). All other reagents were purchased from Sigma (Poole,
Dorset, UK).
MCF-7 cells were cultivated in RPMI 1640 medium containing
2 mM L-glutamine and supplemented with 10% FCS, 100 IU ml–1
penicillin and 100 mg ml–1 streptomycin in an atmosphere of 5%
CO2. Cells were subcultured twice weekly to maintain logarithmic
growth. Variant cell lines were derived from MCF-7wt following
permanent culture in media containing either 10 nM or 10 mM
CJM 126. Media was replaced twice weekly until proliferating
colonies were established. Thereafter, MCF-710 nM 126 and MCF-710
mM 126 cell lines were routinely subcultured twice weekly in the
continued presence of CJM 126.
In vitro growth inhibitory assays
To investigate the effect of agents on growth of MCF-7 sub-lines
cells were seeded into 96-well microtitre plates at densities of 5 ´
103 per well. Once adhered, cells were treated with test agent; final
concentration range between 0.1 nM and 100 mM (n = 8). MTT
conversion assays, performed at the time of drug addition and
following 72 h exposure, monitored cell growth and viability.
Water-soluble 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyl tetra-
zolium bromide (MTT, final concentration 400 mg ml–1) was added
to each well. The following 4 h incubation allowed metabolism of
MTT by mitochondrial dehydrogenases of viable cells to form an
insoluble formazan product. Medium was aspirated and formazan
solubilized by addition of DMSO (100 ml) and glycine buffer
(25 ml). Absorbance, as a measure of viable cell number, was read
at 550 nm on an Anthos Labtec systems plate reader. The efficacy
of each agent reported was examined at least three times.
HPLC anaysis
Medium supporting cell growth was collected (n = 3) and protein
precipitated by addition of HPLC-grade acetonitrile (600 ml) to
300 ml medium. Samples were microcentrifuged at 13 000 rpm for
5 min and supernatant (20 ml,  n = 2) analysed by HPLC.
Separation occurred on a Hypersil ODS reversed phase column
(100 mm ´ 4.6 mm internal diameter) using a mobile phase of
65% methanol and 35% distilled water delivered at a rate of
1 ml min–1. Benzothiazoles and derivatives were detected by UV
at 330 nm. The identities of major biotransformation products
were confirmed by chromatographic analyses of authentic samples.
Confocal laser scanning microscopy
Cells were seeded into sterile petridishes containing a single sterile
coverslip in 10 ml media. They were allowed 24 h to attach before
additional drug was administered to give a final concentration of
30 mM CJM 126. After 24 h exposure, cells were washed five
times in sterile PBS and the coverslips drained. They were
mounted onto glass slides using fluoromount and stored at 4°C in
the dark. Specimens were examined using a Leica TCS4D
confocal laser scanning microscope and UV laser. Images were
stored on an optical disc (230 mb) and photographs produced
using a Sony colour video printer. Parameters, including laser
intensity, brightness and pinhole diameter were constant.
Fluorometric analysis of DNA unwinding
The method adopted for the detection of DNA strand-breaks
utilises the observation that the rate of unwinding of the two DNA
strands in alkali is related to the covalent length of the strands.
Applications of this sensitive and rapid technique include predic-
tion of sensitivity to xenobiotics (Birnboim and Jevcak, 1981).
The fluorescent dye ethidium bromide was used as a direct probe
of DNA structure. Total fluorescence from the presence of double-
stranded DNA plus contaminants was determined. Blank samples
were sonicated lightly and treated with alkali under conditions
which induced complete unwinding of low molecular weight
double-stranded DNA. The difference between these two samples
provided an estimate of the amount of double-stranded DNA.
Experimental samples, including untreated cells and cells exposed
to test agents, were used to estimate the rate of DNA unwinding.
Cell extracts were exposed to alkaline conditions for 1 h, sufficient
to permit partial unwinding of DNA. Fluorescence was read on a
Perkin-Elmer LS-5 luminescence spectrometer: lem 520 nm, lex
590 nm. Samples were measured in triplicate within each experi-
ment; experiments were performed at least three times. The rate of
DNA unwinding in control and treated samples was measured,
allowing agent-induced DNA strand-breaks to be determined.
Western blot procedures
For the detection of NAT1 and NAT2, MCF-7wt, MCF-710 nM 126
and MCF-710 mM 126 cytosolic lysates were prepared and 30 mg
protein loaded onto 12% denaturing polyacrylamide gels.
Electrophoresis was performed at a constant current of 0.06 A for272 TD Bradshaw et al
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1 h. Separated proteins were transferred to polyvinylidene fluoride
(PVDF) membranes (100 v, 1 h) then probed for NAT1 or NAT2
proteins. Immunoblotting with specific abs for wt or mutant p53
and bcl-2 was carried out following separation of proteins (40 mg)
from whole-cell lysates on 10% gels. Incubation with 2° ab linked
to horseradish peroxidase then luminol enhancer:stable peroxide
(1:1) preceeded detection by ECL. Separation (10% gels) of 40 mg
cellular proteins preceeded detection of CYP1A1 bands.
Membranes were incubated (2 h) with goat anti-human polyclonal
1° ab (1: 500 in PBS 0.02%T, 1% milk), immersed in alkaline
phosphatase conjugated rabbit anti-goat 2° ab (1: 5000, 1 h) and
incubated for 10 min with BCIP and NBT substrates in alkaline
phosphatase buffer.
Protein bands were subjected to densitometry using a Sharp
JX330P scanner.
Assay for ethoxyresorufin O-deethylase (EROD) activity
Cells were grown in 75 cm3 flasks and lysates prepared following
desired treatments. Protein content was determined by the method
of Bradford (1976). Reaction mixtures consisting of 760 ml Tris-
HCl buffer (pH 7.4, 100 mM), 10 ml MgCl2 (5 mM), 100 ml
homogenate (5 mg ml–1), 100 ml ethoxyresorufin (1 mM) were
pre-incubated for 5 min at 37°C. Addition of 10 ml NADPH (50
mM) initiated reactions. Blank incubates lacked NADPH.
Following incubation (30 min, 37°C), reactions were terminated
by addition of ice-cold acetonitrile. Samples were centrifuged at
13 000 rpm for 5 min before analysis of supernatant. Fluorescence
was read on a Perkin-Elmer LS-5 luminescence spectrometer: lem
530 nm, lex 585 nm. Samples were measured in triplicate within
each experiment; experiments were performed three times.
RESULTS
In vitro growth inhibition
The unconventional biphasic dose–response relationship
following treatment of MCF-7wt cells with CJM 126 led to the
hypothesis that the mechanism of action may be multifaceted.
Thus, two variant cell lines have been established following long-
term culture of MCF-7wt cells with: (i) a concentration of CJM 126
within the growth inhibitory phase of the dose–response curve
(10 nM); (ii) a concentration within the proliferative phase of the
curve (10 mM). Six months’ continuous exposure to 10 nM or
10 mM CJM 126 gave rise to proliferating MCF-7 colonies which
were able to resist the growth-inhibitory effects of this compound.
Resistance appeared stable in vitro: following 22 passages in the
absence of CJM 126 both variant cell lines revealed IC50 values
> 10 mM when rechallenged with this agent. The doubling time of
MCF-710 nM 126 did not differ significantly from the parent MCF-7
population and was approximately 24 h in log phase; slightly
larger MCF-710 mM 126 cells replicated in approximately 30 h. Figure
2 contrasts the dose–response profiles of MCF-7wt MCF-710 nM 126
and MCF-710 mM 126 to CJM 126. Following treatment for 72 h, IC50
values of <0.001, 69.5 and 74.2 mM, respectively, were calculated.
MCF-710 nM 126 and MCF-710 mM 126 cell lines demonstrated cross-
resistance to DF 129, DF 203, DF 229 and DF 128 (Table 1).
Sensitivity to tamoxifen, BP, doxorubicin, mitomycin C and actin-
omycin D was retained by MCF-710 nM 126 and MCF-710 mM 126 sub-
lines. In addition, the 3 MCF-7 variant cell lines demonstrated
equi-resistance to cisplatin.
Depletion from media of CJM 126 and its
biotransformation by MCF-7 sublines
HPLC detection of CJM 126 enabled comparison of its disappear-
ance from culture media nurturing MCF-7 cell lines. CJM 126 (30
mM) remained stable in medium alone (> 30 days at 37°C, Figure
3A) providing a standard mean peak area and indicating that drug
depletion from media was a consequence of accumulation or
biotransformation within cells.
CJM 126 was rapidly depleted from media sustaining MCF-7wt
and MCF-710 mM 126 cells (84% and 93% depletion in 72 h, Figure
3A). In contrast, MCF-710 nM 126 cultures removed CJM 126 from
medium at a much slower rate revealing 32% loss after 72 h incu-
bation. All three cell lines metabolized CJM 126 (Figure 3B).
HPLC chromatograms revealed distinct preferred routes of
biotransformation of CJM 126 by MCF-710 nM 126 and MCF-
710 mM 126 cells. Like MCF-7wt (Chua et al, 1999), the major
biotransformation product liberated into MCF-710 nM 126 culture
medium was 2-(4-acetylaminophenyl)benzothiazole (DF 128). After
72 h incubations, calculations from mean peak areas indicated an
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Figure 2 Effect of CJM 126 on growth of MCF-7 populations. Cells were
seeded at a density of 5 ´ 103 per well in 96-well microtitre plates (n = 8).
MTT assays performed at the time of drug addition and following 72 h
exposure monitored growth. Data are respresentative of experiments
performed each time the stability of acquired resistance was assessed.
Results are the means ± standard deviations of three experiments.
Table 1 Effect of compounds on growth of MCF-7 populations
IC50(mM)
MCF-7wt MCF-710nM 126 MCF-710 mM 126
CJM 126 <0.001 69.5 74.2
DF 129 <0.001 59.8 64.1
DF 203 <0.001 44.1 60.4
DF 229 <0.001 30.7 47.4
Tamoxifen 0.54 0.25 0.53
BP 0.314 0.077 0.097
Cisplatin >30 >30 >30
Mitomycin C 0.001 0.001 0.002
Doxorubicin 0.005 0.003 0.004
Actinomycin D <0.001 <0.001 <0.001
DF 128 0.001 54.2 65.7
6-OH 126 18.2 10.1 10.4
Cells were seeded at a density of 5 ´ 103 per well and challenged with agent
as described in methods (n = 8). MTT assays (³ 3 per drug) following 72 h
exposure assessed cell growth and viability. Mean IC50 values are given,
standard errors ≤12%Acquired resistance to 2-(4-aminophenyl)benzothiazole 273
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approximate medium concentration of 3.7 mM DF 128.
Chemically synthesized DF 128 failed to inhibit the growth of
MCF-710 nM 126 or MCF-710 mM 126 cells but elicited a biphasic
inhibitory dose–response in MCF-7wt cells (IC50 = 0.001 mM).
Minor metabolites separated included oxidized derivatives of CJM
126. In MCF-710 mM 126 culture medium however, the major
biotransformation product detected was 2-(4-aminophenyl)-6-
hydroxybenzothiazole (6-OH 126, Figure 1). Following 72 h incu-
bation, the approximate concentration of this metabolite detected
in nutrient medium was 5 mM. Such oxidation deprived CJM 126
of growth inhibitory properties (IC50 > 10 mM).
Intracellular drug distribution
Fluorescent compounds may be utilised to facilitate identification
of cellular sites of drug aggregation and thus provide preliminary
information on intracellular targeting. Confocal microscopy,
exploiting the UV fluorescence of the benzothiazole chromophore,
indicated differential intracellular accumulation of CJM 126 in the
three MCF-7 populations following 24 h exposure to 30 mM drug
(Figure 4). All fluorescence observed was drug-derived. An
untreated confluent MCF-7wt cell monolayer observed under
visible light emitted no fluorescence under UV light at the settings
adopted. Fluorescence throughout MCF-7wt cells was observed,
but particularly intense fluorescence was emitted from nuclear
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Figure 3 Uptake and biotransformation of CJM 126 following incubation
with MCF-7wt, MCF-710nM 126 and MCF-710mM 126 cells. Cells were seeded at a
density of 105 per 25 cm3 flask. Following 24 h incubation, CJM 126 was
introduced (final concentration 30 mM). Media samples were removed (two
per time-point) at 24 h intervals and analysed by HPLC. Means ± standard
deviations of three experiments are shown. (A) Depletion of CJM 126 from
nutrient media. (B) Relative levels of CJM 126 and metabolites recovered
from media following 72 h drug exsposure.
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Figure 4 Confocal laser scanning micrographs of (A) MCF-7wt,
(B) MCF-710 nM 126 and (C) MCF-710 nM 126 cells treated for 24 h with
30 mM CJM 126.regions. Fluorescence intensity was significantly reduced in both
acquired-resistant cell lines. CJM 126 was largely restricted to the
cytoplasm of MCF-710 nM 126 cells, but accessed nuclei of MCF-
710 mM 126 cells.
DNA integrity
The rate of DNA unwinding, accurately representing DNA strand-
breaks accrued by MCF-7 populations, was monitored after 24 h
and 72 h exposure to benzothiazole concentrations between 0.01
and 100 mM. MCF-7wt cells accumulated greatest damage. After
24 h treatments, the biphasic dose–response relationship (Figure
2) was reflected in rates of DNA unwinding: for example
maximum strand-breaks followed exposures of 0.3 mM and
³ 50 mM (results not shown). Figure 5 compares DNA unwinding
in MCF-7 populations following 30 mM benzothiazole exposure
for 72 h, prior to death of MCF-7wt cells. Significantly reduced
strand-breaks were incurred by the two MCF-7 variant popula-
tions. In particular, damage to MCF-710 nM 126 cells appeared
negligible upon benzothiazole treatment.
Protein expression
Western blot experiments demonstrated expression of both NAT1
and NAT2 proteins in all three MCF-7 cell lines. Significantly
enhanced (> 170% compared to MCF-7wt) expression of NAT2
protein was detected within the cytoplasm of MCF-710 nM 126 cells
(Figure 6A), consistent with their superior acetylation efficacy.
CYP1A1 expression was powerfully induced in MCF-7wt and
MCF-710 nM 126 cells by 50 mM CJM 126 (72 h). However, constitu-
tive expression of CYP1A1 was detected only in MCF-710 mM 126
cells, whether cultured routinely in the presence of 10 mM CJM
126 (Figure 6B) or following drug absence for 14 days. Further
induction by CJM 126 (50 mM, 72 h) was slight.
Substantial expression of bcl-2 protein was detected in MCF-7wt
lysates. Up-regulation of this protein by approximately 25% 
was consistantly detected in MCF-7 populations with acquired
resitance to CJM 126 (Figure 6A).Use of specific antibodies
distinguishing wt and mutant p53 demonstrated significantly
enhanced expression of wt p53 in both CJM 126-resistant MCF-7
sub-lines. Protein detected in MCF-710 nM 126 and MCF-710 mM 126
lysates respectively was 23-fold and 27-fold greater than untreated
MCF-7wt cells, which expressed very low basal levels of wt p53
(Figure 6A). 
CYP1A1 activity in MCF-7 lysates
Ethoxyresorufin  O-de-ethylation is catalyzed by CYP1A1.
CYP1A1 activity was assessed by measurement of reaction
product resorufin. Negligible EROD activity was detected in
untreated MCF-7wt lysates following 30 min incubation at
37°C. Incubates containing MCF-710 nM 126 lysates produced low
levels of resorufin. Significant constitutive CYP1A1 activity in
274 TD Bradshaw et al
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Figure 5 Effect of benzothiazole molecules (30 mM) on DNA unwinding
following 72 h exposure. DNA unwinding after 1 h was measured in MCF-7wt,
MCF-710 nM 126 and MCF-710 mM 126 cells by fluorometric analysis, enabling
detection of agent-induced DNA strand-breaks. 0% represents total amount
of double-stranded DNA. 100% represents complete unwinding of low
molecular weight double-stranded DNA. Experiments were performed at
least three times and measurements were carried out in triplicate for each
experiment. Means ± standard deviations are shown.
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Figure 6 (A) Relative expression of NAT1, NAT2, bcl-2 and wt p53 proteins
in MCF-7 populations. Blots were performed at least three times from three
separate sample preparations. Expression of NAT1, NAT2 and bcl-2 in MCF-
7wt lysates represents 100%. Expression of p53 in MCF-710 mM 126 lysates
represents 100%. (B) Expression of CYP1A1 (constitutive and induced) in
MCF-7wt, MCF-710nM 126 and MCF-710nM 126 control cell lysates and following
exposure of cells to 50 mM CJM 126 (72 h) respectively. Immunoblot of
recombinant CYP1A1 microsomes (10 mg protein) represents the positive
control, against which sample CYP1A1 expression was compared. Blots
were performed twice on two separate sample preparations. Means ±
standard deviations are shown.Acquired resistance to 2-(4-aminophenyl)benzothiazole 275
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MCF-
710 mM 126 lysates catalysed production of 26.9 nM resorufin per mg
protein. After treatment of cells with 30 mM CJM 126 for 72 h,
increased EROD activity in MCF-7wt lysates was demonstrated by
sharp rises in resorufin (> 20-fold, Figure 7). Activity was further
induced in MCF-710 nM 126 and MCF-710 mM 126 incubates by 260%
and 42% respectively.
DISCUSSION
Two MCF-7 sub-lines have been established which display resis-
tance to the prototype analogue of an intriguing and unique class
of antitumour agent, the 2-(4-aminophenyl)benzothiazoles.
Acquired resistance to CJM 126 conferred cross-resistance to 3¢
substituted analogues (Table 1). In the NCI COMPARE program
Pearson Correlation Coefficients above 0.7 were observed only
between 2-(4-aminophenyl)benzothiazole analogues (Bradshaw
et al, 1998b). Such observations indicate shared mechanisms of
action. Evolution of resistance requires that sensitive cells acquire
multiple genetic and biochemical modifications (Hayes and Wolf,
1990) which may be pertinent to drug action. Cognate adaptations
to promote survival in the presence of 2-(4-aminophenyl)benzo-
thiazoles have been detected in MCF-710 nM 126 and MCF-710 mM 126
cell lines. In addition, distinct mechanisms have evolved as a
consequence of selection in the presence of concentrations of
CJM 126 which elicit very different growth responses in MCF-7wt
cells.
We have shown that cells lines inherently sensitive to this class
of agent rapidly sequester and metabolize 2-(4-amino-
phenyl)benzothiazoles, whereas no net uptake was detected by
intrinsically resistant cell lines (Chua et al, 1999; Kashiyama et al
1999). Compared with MCF-7wt and MCF-710 mM 126, MCF-710 nM 126
cells, selected in the presence of the more cytotoxic concentration
of 10 nM CJM 126, demonstrated dramatically impaired depletion
of CJM 126 from media (Figure 3A) with predominantly cyto-
plasmic intracellular drug localization (Figure 4). Accordingly,
negligible DNA strand-breaks were incurred by this sub-line when
challenged with 2-(4-aminophenyl)benzothiazole analogues
(Figure 5) reflecting their poor sensitivity. Access to nuclei may be
essential for CJM 126-induced growth inhibition in MCF-7wt;
nuclear exclusion by MCF-710 nM 126 may aid emergence of
resistance.
However, cells selected in the presence of 10 mM CJM 126 (the
proliferative phase) rapidly depleted culture medium of CJM 126
(Figure 3A), accumulated CJM 126-associated fluorescence
within nuclei (Figure 4) and sustained levels of DNA strand-
breaks greater than MCF-710 nM 126 but less than MCF-7wt
(Figure 5).
The major biotransformation product of CJM 126 extruded by
MCF-7wt cells is DF 128 (Figure 1). Activity was retained in MCF-
7wt, but with diminished potency. Cross-resistance to DF 128 was
observed in both MCF-7 variant cell lines. Similarly, acetylation
was the major metabolic route of CJM 126 in MCF-710 nM 126 cells.
Consistant with this observation, cytoplasmic levels of NAT1 and
particularly NAT2 proteins were elevated in the MCF-710 nM 126
sub-line.
In humans, NAT1 and NAT2 isoenzymes catalyse N-acetyla-
tion,  O-acetylation and N-O-transacetylation of arylamines
(Sadrieh et al, 1996). Two polymorphic loci on chromosome 8p22
encode these enzymes segregating individuals into fast and slow
acetylator phenotypes (Stacey et al, 1996). Thus, acetylation
capacity and the balance between xenobiotic activation/detoxifica-
tion is subject to individual variation and, with it, the response to
chemotherapeutic agents. Continued exposure of MDA 468 cells,
which express only NAT1, to 10 nM or 10 mM CJM 126 has failed
to generate resistant variants of this cell line, supporting a role for
NAT2 in acquired resistance to CJM 126.
Biotransformation via C-oxidation was the preferred metabolic
route of CJM 126 by MCF-710 mM 126 cells; 6-OH 126 was the major
metabolite rapidly detected in nutrient medium.
The role of enzymes responsible for C-oxidation, specifically
CYP1A1 (Pelkonen and Raunio, 1997; Kress and Greenlee, 1997)
has been investigated. CYP1A1 catalyzes both detoxification and
activation of xenobiotics and precarcinogens (Crofts et al, 1998).
Recombinant CYP1A1 catalyzed C-6 oxidation of the benzothia-
zole nucleus (Chua et al, submitted) producing metabolites which:
(i) like a-naphthoflavone and apigenin (Pastrakuljic et al, 1997),
inhibit CYP1A1 activity and abrogate growth inhibition induced
by 2-(4-aminophenyl)benzothiazoles; (ii) like apigenin, evoke a
mitogenic response between concentrations of 300 nM and 5 mM
in MCF-7wt cells. Covalent binding between 14C labelled DF 203
and CYP1A1 further implicated this isoform as a molecular
target for this class of agent. Moreover, in a panel of cell lines
examined induction of CYP1A1 expression and activity by
2-(4-aminophenyl)benzothiazole was restricted to cell lines inher-
ently sensitive to this class of agent. Significant induction by
CJM 126 of CYP1A1 expression and activity was detected in
MCF-7wt and MCF-710 nM 126 lysates (Figure 6B and 7). However,
oxidized derivatives comprised only minor biotransformation
products of CJM 126 incubations with MCF-7wt and MCF-710 nM 126
cells. The stable constitutive expression and activity of CYP1A1
in MCF-710 mM 126 cells may equip this sub-line with the ability to
biotransform potentially damaging agents to non-toxic derivatives
possessing growth-promoting stimuli which may assist survival of
MCF-710 mM 126 cells in the presence of 2-(4-aminophenyl)benzoth-
iazole. Alternatively, meagre inducibility of CYP1A1 expression
and activity in this cell line could lead to failure in activation of
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2-(4-aminophenyl)benzothiazole and thus contribute to drug
resistance. Ivy et al (1988) report low inducibility of CYP1A1 in
multidrug-resistant MCF-7/Adr cells; indeed this cell line failed to
respond to CJM 126 and in lysates prepared from CJM 126 treated
cells, no expression of CYP1A1 protein was observed (data not
shown).
The response of MCF-710 nM 126 and MCF-710 mM 126 cells to BP,
the precarcinogen catalyzed to its reactive metabolite by CYP1A1,
was of interest considering the implicated role of CYP1A1 in the
mechanism of action of 2-(4-aminophenyl)benzothiazoles. In fact,
marginally greater sensitivity was displayed by MCF-710 nM 126 and
MCF-710 mM 126 cell lines indicating distinct mechanisms of resis-
tance to CJM 126 and BP in MCF-7 sub-lines. Acquired resistance
to BP was mediated by decreased activation to (+/–)-anti-
benzo[a]pyrene-7, 8-diol, 9, 10-oxide (Caruso and Batist, 1999).
The three MCF-7 variant lines appeared resistant to the DNA-
damaging effects of cisplatin, but displayed equi-sensitivity to
mitotmycin C which cross-links and alkylates DNA. MCF-
710 nM 126 and MCF-710 mM 126 sub-lines also retained sensitivity to
doxorubicin and actinomycin D. Comparative genomic hybridiza-
tion experiments confirmed under-representation of the MDR1
region (7q21) in both resistant cell lines (L Hiorns, personal
communication); inferring that acquired resistance to CJM 126 is
not mediated by p-glycoprotein overexpression.
Deregulation of apoptotic machinery may serve as a novel
mechanism of resistance by influencing the propensity of cells to
undergo drug-induced apoptosis. In MCF-7wt cells exposed to 2-
(4-aminophenyl)benzothiazoles, induction of wt p53 expression is
concentration-dependent, biphasic and inversely proportional to
growth inhibition and bcl-2 expression. Both MCF-710 nM 126 and
MCF-710 mM 126 variants exhibit greatly enhanced levels of wt p53.
Elevated p53 may promote survival in the presence of cytotoxins
by arresting cells in the G1 cell cycle phase, permitting repair of
damaged DNA such that cells, rescued from the apoptotic
pathway, are offered a growth advantage in the presence of the
survival signal provided by enhanced bcl-2 expression
(Malcomson et al, 1995; Kinzler and Vogelstein, 1994). However,
sensitivity to 2-(4-aminophenyl)benzothiazoles does not depend
upon functional p53 or bcl-2 expression as exemplified by the
equi-sensitive human breast carcinoma cell line MDA 468. Failure
of these cells, which possess mutant p53 and are bcl-2 null, to
spawn acquired resistant phenotypes may signify a role for these
proteins in acquired resistance.
In conclusion, it is worth stressing that anti-cancer drug resis-
tance is a multifactorial phenomenon. Decreased intracellular drug
levels (anthracyclines, vinca alkaloids and antibiotics), increased
drug inactivation (alkylating agents and antimetabolites), altered
expression of drug metabolizing enzymes, target enzymes or
receptors (methotrexate or steroids), all exemplify strategies which
may have been adopted by MCF-7 cells as they acquire resistance
to 2-(4-aminophenyl)benzothiazoles.
Knowledge of acquired resistance mechanisms may serve as an
important prerequisite in novel drug discovery programmes to
guide rational chemical synthesis of superior analogues. Hydrogen
atoms in the benzothiazole nucleus have been isosterically
replaced with fluorine atoms to eliminate inactivating 6-hydroxy-
lation and hence proliferation associated with drug exposures
between 1 mM and 30 mM (unpublished). In preliminary studies, a
fluorinated derivative of CJM 126 elicited nM IC50 values in MCF-
7wt, MCF-710 nM 126 and MCF-710 mM 126 cell lines. Moreover, the
second proliferative phase associated with MCF-7 exposure to
CJM 126 was absent, indicating that by molecular modification,
acquired resistance to CJM 126 may be circumvented.
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